Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313967 | 0.98 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10507979 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL11304206 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL16426789 | 0.80 | FFAR3 (0.41) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL3631729 | 0.77 | ALDH1A1 (0.71) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL1743259 | 0.76 | TLR4 (0.32) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL9298979 | 0.76 | MAPT (0.55) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL9193723 | 0.76 | ALDH1A1 (0.53) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL15457517 | 0.74 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10887665 | 0.74 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108531514-B | Endogenous hyperbranched polyspermine cationic gene vector and preparation method and application thereof | 暨南大学 | 2020-08-07 | — | — | CN | claimed |
| US-20260139007-A1 | EPHA4 ANTAGONISTS AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260078149-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | VIKING THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4651910-A1 | DUAL LABELLED COMPOUNDS TARGETING THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12421282-B2 | Compositions and methods for the treatment of metabolic and liver disorders | VIKING THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-0977763-A1 | PROTECTED AMINOSUGARS | Alchemia Pty. Ltd. (AU) | 2000-02-09 | — | — | EP | disclosed |
| EP-0672701-B1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AG (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999031049-A1 | NEUROPROTECTIVE AGENTS | UNIVERSITY OF SOUTHAMPTON (GB) | 1999-06-24 | — | — | WO | disclosed |
| EP-0923528-A1 | OLIGOSACCHARIDE SYNTHESIS | Alchemia Pty. Ltd. (AU) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998038197-A1 | PROTECTED AMINOSUGARS | ALCHEMIA PTY. LTD. (AU) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998008799-A1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY. LTD. (AU) | 1998-03-05 | — | — | WO | disclosed |
| EP-0672701-A1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0128479-B1 | PYRAZOLE DERIVATIVES WITH AN ERGOLINE SKELETON, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1990-08-01 | — | — | EP | disclosed |
| US-4632928-A | POTENT PGF2 RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-12-30 | — | — | US | disclosed |
| EP-0128479-A2 | Pyrazole derivatives with an ergoline skeleton, a process for preparing them and pharmaceutical compositions containing these compounds | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421282-B2 | Compositions and methods for the treatment of metabolic and liver disorders | GIPR, GLP1R, GPR119 | ALDH1A1 2795/4885MAPT 4598/4885KDM4E 4477/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | ALDH1A1 4342/4885MAPT 1878/4885KDM4E 1839/4885 |
| US-20260139007-A1 | EPHA4 ANTAGONISTS AND USES THEREOF | EPHA4, EPHA1, EPHB4 | ALDH1A1 3696/4885MAPT 2000/4885KDM4E 2599/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | ALDH1A1 3103/4885MAPT 4113/4885KDM4E 4319/4885 |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | SEM1, REN, SETDB1 | ALDH1A1 355/4885MAPT 2495/4885KDM4E 1094/4885 |
| US-20260078149-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | GLP1R, SLC10A1, GIPR | ALDH1A1 3683/4885MAPT 3324/4885KDM4E 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.